drugset / Trial / NCT01141491

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

NCT01141491

Phase 2 Completed 136 enrolled MabVax Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Sarcoma patients are at high risk for their cancer to recur even when the sarcoma has been removed surgically or treated with radiation or chemotherapy. The patients in the study will be randomized (like flipping a coin) to receive either a vaccine that is combined with an immune system stimulant or the immune system stimulant alone. The immune system stimulant is called OPT-821 and is an immunological booster. The trivalent vaccine is being developed to teach the patient's immune system to recognize 3 types of sugars called GM2, GD2 and GD3 that are found primarily on the surface of sarcoma cells. If the trivalent vaccine can stimulate the patient's immune system to develop antibodies which recognize and target the GM2, GD2 and GM3 sugars, then the patient's antibodies could attack and kill any remaining sarcoma cells potentially preventing the recurrence of sarcoma.

Timeline

Start
2010-06
Primary completion
2013-09
Completion
2017-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Trivalent ganglioside vaccine Vaccine Subcutaneous
Comparator OBI-821 Other / unclassified 150 ug Subcutaneous

Indications